CONMED CNMD Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 55.2%+0.6pp | 54.6%+0.4pp | 54.2%-1.8pp | 56.1%-0.1pp | 56.1%+0.1pp | |
| Operating margin | 8.2%+0.7pp | 7.5%-1.3pp | 8.8%-4.2pp | 13%-0.8pp | 13.8%-1.6pp | |
| Net margin | 4%+0.6pp | 3.4%-1.3pp | 4.8%-3.6pp | 8.3%-0.7pp | 9%-1.1pp | |
| EBITDA margin | 12%+0.7pp | 11.3%-1.4pp | 12.7%-4.3pp | 16.9%-0.8pp | 17.7%-1.6pp | |
| Free cash flow margin | 9%-1.9pp | 11%-0.1pp | 11.1%-0.1pp | 11.2%-1.3pp | 12.5%+0.7pp | |
| Returns | ||||||
| Return on equity | 5.5%+0.8pp | 4.7%-1.9pp | 6.6%-5.1pp | 11.7%-1.3pp | 13%-1.8pp | |
| Return on assets | 2.4%+0.3pp | 2%-0.7pp | 2.8%-2.0pp | 4.8%-0.4pp | 5.2%-0.6pp | |
| Return on invested capital | 4.1%+0.5pp | 3.6%-1.2pp | 4.8%-2.7pp | 7.5%-0.6pp | 8.1%-0.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | |
| Inventory turnover | 1.7×-0.1× | 1.8×0.0× | 1.7×0.0× | 1.7×0.0× | 1.7×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.3×+0.2× | 2.1×0.0× | 2.1×-0.1× | 2.2×0.0× | 2.3×0.0× | |
| Quick ratio | 1×0.0× | 1×+0.1× | 0.9×-0.1× | 1×0.0× | 1×-0.1× | |
| Cash ratio | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.8×0.0× | 0.9×0.0× | 0.8×0.0× | 0.9×0.0× | 0.9×-0.1× | |
| Debt-to-assets | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Net debt / EBITDA | 5×-0.4× | 5.5×+0.7× | 4.8×+1.0× | 3.8×+0.1× | 3.7×0.0× | |
| Interest coverage | 3.8×+0.5× | 3.3×-0.3× | 3.6×-1.4× | 5×0.0× | 5×-0.3× | |
| Per Share | ||||||
| Book value per share | $33.23+0.2% | $33.17+2.1% | $32.47+0.6% | $32.29+2.9% | $31.38+1.6% | |
| Valuation | ||||||
| Market capitalization | $1.04B-35.6% | $1.26B-13.6% | $1.46B-11.0% | $1.63B-12.4% | $1.87B-11.7% | |
| Enterprise value | $1.87B-24.5% | $2.11B-7.3% | $2.27B-8.5% | $2.49B-8.8% | $2.73B-10.3% | |
| Price / earnings | 19×+5.4× | 26.7×+4.0× | 22.7×+7.9× | 14.8×-0.9× | 15.7×-0.2× | |
| Price / sales | 0.8×-0.5× | 0.9×-0.2× | 1.1×-0.2× | 1.2×-0.2× | 1.4×-0.2× | |
| Price / book | 1×-0.6× | 1.2×-0.2× | 1.4×-0.2× | 1.6×-0.3× | 1.9×-0.3× | |
| EV / EBITDA | 11.4×+0.7× | 13.6×+0.3× | 13.3×+2.2× | 11.1×-0.6× | 11.7×-0.4× | |
| EV / sales | 1.4×-0.5× | 1.5×-0.2× | 1.7×-0.2× | 1.9×-0.2× | 2.1×-0.3× | |
| Free cash flow yield | 11.9%+1.7pp | 12%+1.8pp | 10.2%+1.2pp | 9.1%+0.3pp | 8.8%+1.5pp | |
| Earnings yield | 5.3%-2.1pp | 3.7%-0.7pp | 4.4%-2.3pp | 6.7%+0.4pp | 6.4%+0.1pp | |
| Dividend yield | 1.8%+0.3pp | 2%+0.3pp | 1.7%+0.2pp | 1.5%+0.2pp | 1.3%+0.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are CONMED's profit margins?
- CONMED (CNMD) runs a 55.2% gross margin and a 8.2% operating margin, with a 4.0% net margin.
- Where do CONMED's ratios come from?
- Every ratio is computed from CONMED's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
